These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14713822)

  • 1. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity.
    Reitz A; Schurch B
    J Urol; 2004 Feb; 171(2 Pt 1):804; discussion 804-5. PubMed ID: 14713822
    [No Abstract]   [Full Text] [Related]  

  • 2. Botulinum toxin type B for type A resistant bladder spasticity.
    Pistolesi D; Selli C; Rossi B; Stampacchia G
    J Urol; 2004 Feb; 171(2 Pt 1):802-3. PubMed ID: 14713821
    [No Abstract]   [Full Text] [Related]  

  • 3. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?
    Pistolesi D; Giannarini G; Stampacchia G; Selli C
    Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198
    [No Abstract]   [Full Text] [Related]  

  • 5. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report.
    Dykstra DD; Pryor J; Goldish G
    Arch Phys Med Rehabil; 2003 Sep; 84(9):1399-400. PubMed ID: 13680581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
    Grosse J; Kramer G; Stöhrer M
    Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin therapy for neurogenic detrusor overactivity.
    Smaldone MC; Ristau BT; Leng WW
    Urol Clin North Am; 2010 Nov; 37(4):567-80. PubMed ID: 20955908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Harris MA; Harding C; Fulford S; Whiteway J
    BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
    [No Abstract]   [Full Text] [Related]  

  • 14. New therapeutic options for refractory neurogenic detrusor overactivity.
    Giannantoni A; Mearini E; Di Stasi SM; Costantini E; Zucchi A; Mearini L; Fornetti P; Del Zingaro M; Navarra P; Porena M
    Minerva Urol Nefrol; 2004 Mar; 56(1):79-87. PubMed ID: 15195033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
    Chen CY; Liao CH; Kuo HC
    Spinal Cord; 2011 May; 49(5):659-64. PubMed ID: 21243000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A day case technique for administration of intradetrusor Botulinum toxin B under sedo-analgesia in neuropathic and non-neuropathic detrusor overactivity: Endoscopic Neurostabilisation (ENS).
    Ghei M; Nathan S; Maraj BH; Malone-Lee JG; Miller R
    Int Urol Nephrol; 2005; 37(3):471-2. PubMed ID: 16307321
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment with botulinum toxin in neurologic pediatrics].
    Justus N; Lee SH; Berweck S; Heinen F
    Kinderkrankenschwester; 2007 Jul; 26(7):274-6. PubMed ID: 17726921
    [No Abstract]   [Full Text] [Related]  

  • 19. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
    Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.